+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 61 Actively Recruiting clinical trials

C

Actively Recruiting

This research aims to compare two approaches for treating previously untreated amblyopia in children aged 3 to under 13 years. It evaluates whether using glasses and patching at the same time leads to similar improvements in vision as first using glasses alone, followed by patching only if needed. The trial focuses on children with amblyopia caused by differences in eye alignment or prescription errors. Children will be assigned randomly to one of two treatment groups one group will wear glasses full-time and add patching for 2 hours daily only if there is no improvement after glasses alone the other group will wear glasses and patch the weaker eye for 2 hours daily at the same time from the start. Vision tests will be done at baseline and follow-up visits every 8 weeks for up to 56 weeks. Participants will have their distance visual acuity measured with trial frames before and after getting their glasses to confirm eligibility. During the study, vision will be monitored to classify improvement or stability, guiding whether patching is needed in the sequential group. Outcomes include changes in vision clarity after 56 weeks and quality-of-life assessments. Regular visits help track progress and safety until study completion.

Age: 3Years - 13YearsAll GendersPhase 3
68 locations
C

Actively Recruiting

Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.

Age: 18Years +All GendersPhase 3
206 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of glofitamab alone compared with the choice of either rituximab plus bendamustine or lenalidomide with rituximab in patients with relapsed or refractory mantle cell lymphoma. This Phase III study aims to determine which treatment better controls the disease in adults who have already received prior therapies, including a BTK inhibitor. The study involves random assignment to one of the treatment groups to compare outcomes over time. Participants assigned to the glofitamab group will receive two intravenous doses of obinutuzumab before starting intravenous glofitamab, given in 12 cycles of 21 days each. Those in the comparator group will receive either bendamustine plus rituximab for up to six 28-day cycles or rituximab plus oral lenalidomide daily for 21 days in 28-day cycles until the disease worsens. Tocilizumab may be given intravenously as needed to manage side effects related to immune response. During the study, participants will undergo regular assessments to monitor disease progression, response to treatment, physical functioning, fatigue, and lymphoma symptoms using questionnaires and clinical evaluations. Researchers will also measure drug levels and immune responses up to 24 months after randomization. Safety and effectiveness will be closely tracked, including survival and duration of response, to understand the benefits and risks of each treatment option.

Age: 18Years +All GendersPhase 3
83 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
T

Actively Recruiting

Researchers are studying heavy drinking young adults aged 18 to 26 to see how brief training in craving regulation affects alcohol consumption. This Stage 1B randomized controlled trial compares two active training methods based on cognitive-behavioral therapy CBT and mindfulness-based therapy MBT with a control group receiving no strategy. The study aims to understand if these approaches can reduce heavy drinking and related negative consequences. Participants are randomly assigned to one of three groups CBT-ROC-T training, MBT-ROC-T training, or a control group with no craving regulation strategy. Each participant will complete four 45-minute web-based sessions over three weeks. The study spans 16 weeks, including three weeks before intervention, three weeks during intervention, and ten weeks after intervention. Participants will undergo screening by phone and online, followed by in-person eligibility confirmation and baseline assessments. Throughout the study, they will complete training sessions, post-intervention assessments, and 1-2 follow-up assessments via phone or online. Researchers will measure changes in heavy drinking frequency, estimated blood alcohol concentration, alcohol-related negative consequences, and WHO drinking risk levels. Data will be collected using craving ratings and questionnaires during exposure to alcohol-related stimuli.

Age: 18Years - 26YearsAll GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Researchers are evaluating the effects of a high-intensity exercise program specifically designed for individuals with chronic post-stroke aphasia. This randomized trial aims to determine whether participating in this program leads to improvements in physical health, language, cognitive, motor recovery, psychological, and psychosocial areas compared to a low-intensity exercise program. The study will assess both short- and long-term effects over several months. Participants will be randomly assigned to one of two groups one group will engage in a 12-week high-intensity interval training full-body workout called Aphasia Physical EXercise APEX, tailored to accommodate stroke survivors motor abilities and fitness levels. The other group will participate in a 12-week low-intensity non-aerobic exercise program that reflects standard physical therapy without cardiovascular or strengthening components. Both interventions are delivered in group settings. During the study, participants will undergo evaluations at multiple time points, including baseline, pre-treatment, post-treatment, and a 3-month follow-up. Assessments include language testing with the Western Aphasia Battery and other language and cognitive tests, physical fitness measures like aerobic capacity and gait speed, as well as motor performance and functional tests. Researchers will monitor changes in these areas to understand the impact of the exercise programs on recovery after stroke.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
4 locations
R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a multi-component chlorination intervention in health care facilities in western Kenya to improve maternal and neonatal health. This study focuses on reducing bacterial contamination, including antibiotic resistant bacteria, in water supplies, on staff hands, and on high-touch surfaces in maternity wards. The trial is a cluster randomized controlled design involving 36 medium-sized public health facilities to determine effects on bacterial carriage and symptoms of serious infection in mothers and newborns. The intervention group facilities receive passive inline chlorine dosers that automatically treat water accessed by maternity wards, plus a reliable supply of chlorine disinfectant through either on-site electrochlorination or bulk delivery. Both intervention and control groups receive infection prevention and control messaging. Facilities also get hardware for surface disinfection. Control group facilities will receive chlorine dosers after the trial ends. Participants include pregnant adults or mature minors giving birth at enrolled facilities and their newborns. Researchers will collect samples and follow mother-neonate pairs to measure bacterial colonization and signs of infection within the first week after birth. Environmental samples and water quality are monitored over 24 months. The primary outcomes include possible serious bacterial infections and sepsis symptoms in neonates and mothers, as well as bacterial presence and antibiotic resistance in samples from neonates, mothers, environments, and water supplies.

All AgesAll GendersPhase Not Applicable
2 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations

1-10 of 61

1